Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HER2-specific T cells

Phase 1Biologic

BBaylor College of Medicine

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain Tumor, RecurrentActive, not recruiting

Brain Tumor, RecurrentPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2037

Phase 1Active, not recruiting

Brain Tumor, Recurrent

NCT02442297

Clinical

Trials by Indication[1]

Brain Tumor, Recurrent1 trial

Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR)

Active, not recruiting·BBaylor College of Medicine·Phase 1·NCT02442297·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HER2-specific T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER2-specific T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER2-specific T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baylor College of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBaylor College of Medicine

Related News